Related Experiment Video
Updated: May 16, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Targeting death receptor TRAIL-R2 by chalcones for TRAIL-induced apoptosis in cancer cells
Ewelina Szliszka1, Dagmara Jaworska, Małgorzata Ksek
1Chair and Department of Microbiology and Immunology, Medical University of Silesia in Katowice, Jordana 19, 41-808 Zabrze, Poland. wkrol@sum.edu.pl.
Abstract:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells without toxicity to normal cells. TRAIL binds to death receptors, TRAIL-R1 (DR4) and TRAIL-R2 (DR5) expressed on cancer cell surface and activates apoptotic pathways. Endogenous TRAIL plays an important role in immune surveillance and defense against cancer cells. However, as more tumor cells are reported to be resistant to TRAIL mediated death, it is important to search for and develop new strategies to overcome this resistance. Chalcones can sensitize cancer cells to TRAIL-induced apoptosis. We examined the cytotoxic and apoptotic effects of TRAIL in combination with four chalcones: chalcone, isobavachalcone, licochalcone A and xanthohumol on HeLa cancer cells. The cytotoxicity was measured by MTT and LDH assays. The apoptosis was detected using annexin V-FITC staining by flow cytometry and fluorescence microscopy. Death receptor expression was analyzed using flow cytometry. The decreased expression of death receptors in cancer cells may be the cause of TRAIL-resistance. Chalcones enhance TRAIL-induced apoptosis in HeLa cells through increased expression of TRAIL-R2. Our study has indicated that chalcones augment the antitumor activity of TRAIL and confirm their cancer chemopreventive properties.
Insights
Chalcones can enhance cancer cell sensitivity to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) therapy. This study shows chalcones increase TRAIL-R2 expression, overcoming TRAIL resistance and augmenting antitumor activity.
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cancer cell apoptosis.
- Cancer cells can develop resistance to TRAIL-mediated apoptosis.
- Chalcones are investigated for their potential to overcome this resistance.
Purpose of the Study:
- To evaluate the combined cytotoxic and apoptotic effects of TRAIL with four chalcones on HeLa cancer cells.
- To investigate the role of chalcones in modulating TRAIL death receptor expression.
- To confirm the cancer chemopreventive properties of chalcones.
Main Methods:
- Cytotoxicity assessed using MTT and LDH assays.
- Apoptosis detected via annexin V-FITC staining (flow cytometry and fluorescence microscopy).
- Death receptor expression analyzed by flow cytometry.
Main Results:
- Chalcones sensitized HeLa cancer cells to TRAIL-induced apoptosis.
- Chalcones increased the expression of TRAIL-R2 (death receptor).
- This suggests chalcones can overcome TRAIL resistance by upregulating death receptors.
Conclusions:
- Chalcones augment the antitumor activity of TRAIL.
- Chalcones demonstrate cancer chemopreventive properties by enhancing TRAIL-mediated apoptosis.
- Targeting TRAIL-R2 expression with chalcones is a potential strategy against TRAIL-resistant cancers.
